BioSpace News Archive

In age of COVID-19, non-communicable diseases put patients at increased risk of complications

Immunovia AB (publ) (“Immunovia”) today provides an update on the actions that the company is taking in response to the coronavirus (COVID-19) pandemic. During these challenging times, Immunovia remains focused on the sales start of the fi

QuVa Pharma, Inc. confirms its ability to provide essential medicines on shortage for the treatment of critically ill COVID-19 patients given the Food and Drug Administration’s (FDA) announcement of the “Temporary Policy for Compounding of Certain Drugs for Hospitalized Patients by Outsourcing Facilities During the COVID-19 Public Health Emergency”,

Globant (NYSE: GLOB), a digitally-native technology services company, today announced the launch of its Life Sciences Studio.

Hetero, one of India’s leading generic pharmaceutical companies and the world’s largest producer of anti-retroviral drugs, announced today that it has entered into a licensing agreement with Gilead Sciences, Inc. for the manufacturing and distribution of “Remdesivir” for the treatment of Covid-19

HTG Molecular Diagnostics, Inc., a life science company whose mission is to advance precision medicine, reported its financial results for the first quarter ended March 31, 2020.

Bexion Pharmaceuticals announced today that the following three abstracts submitted to the 2020 American Society of Clinical Oncology (ASCO) have been accepted for oral or poster presentation: Oral Pre

IVX Health, a national network of patient-focused care centers providing biologic infusion and injection therapy, is collaborating with hospitals and health systems across the country to ensure a safe, accessible site of care for immunocompromised patients during the COVID-19 pandemic.

TRACON Pharmaceuticals, a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., announced financial results for the first quarter ended March 31, 2020.